PRODUCT · SERVICE PLATFORM
PortraiTARGET
Smarter target discovery for ADCs, RPTs, and bispecifics — powered by spatial biology
PortraiTARGET™ leverages spatial transcriptomics, AI modeling, and multi-scale validation to unlock novel targets and design smarter therapies — from tumor-selective ADCs to dual-targeting degraders.
- MODALITY COVERAGE
- ADC · RPT · Bispecific · Degrader
- ANALYSIS DEPTH
- Spatial transcriptomics + AI + Microscopic-PK
- OUTCOME
- De-risked, tumor-selective targets
WHY PORTRAITARGET
Bulk-RNA misses what the tissue tells you.
Standard pipelines treat tumors as a single bag of cells. PortraiTARGET reads the actual spatial architecture — neighborhood context, payload reach, off-target risk — and turns it into actionable target intelligence.
- 01
Spatial-first target intelligence
Intra-tumoral expression, neighborhood context, and whole-body toxicity in one analysis. Tumor-selective targets surface where bulk-RNA averages would have hidden them.
- 02
Physics-aware drug design
Microscopic-PK modeling of vessel density, internalization kinetics, and linker cleavage — payload delivery is simulated before any molecule is synthesized.
- 03
De-risked at every step
Multi-scale validation — from spatial co-localization in tissue to dose maps in vivo — catches efficacy and safety risks while they are still cheap to fix.
WHAT IT DOES
From spatial data to a viable target
Six analyses on one platform — covering target selection, payload optimization, and dose prediction across modalities.
- Target selection
Molecular-to-Spatial Target Mapping
Maps intra-tumoral expression, neighborhood context, and whole-body toxicity to surface actionable, tumor-selective targets.
- Heterogeneity check
ITEM Analysis
Intra-Tumoral Expression Mapping evaluates spatial heterogeneity and pinpoints targets with consistent tumor expression and minimal off-target spillover.
- ADC efficacy forecast
Bystander Effect Quantification
Mean Target-High Distance (MTHD) identifies spatial configurations where low-expressing cells benefit from neighboring high-expressing regions — forecasting ADC response.
- Modality pairing
Optimized Payload Strategies
Match ADC linkers to cleavage-enzyme zones, model RPT spread by vasculature & hypoxia, and identify dual-target zones co-localizing with E3 ligase for degraders.
- Payload delivery
Microscopic-PK Dynamic Concentration Maps
Physics-based modeling of vessel density, target abundance, and internalization kinetics produces high-resolution temporal maps of payload delivery — and the share of tumor cells exceeding IC50.
- RPT dosimetry
Radiation Dose Prediction
Estimates absorbed radiation dose (Gy) in tumor tissues for agents like Lu-177, accounting for vessel proximity, receptor targeting, and microenvironmental barriers.
MODALITIES
Built for the modalities reshaping oncology
Spatial biology is modality-aware by default — the same platform decodes ADCs, RPTs, bispecifics, and degraders without rebuilding the analysis stack.
ADCs
Tumor-selective targets, linker-payload pairing against cleavage-enzyme zones, and bystander-effect forecasting via MTHD.
RPTs
Radiopharmaceutical therapies modeled by vasculature and hypoxia distribution, with absorbed-dose maps for Lu-177 and similar agents.
Bispecifics
Dual-target spatial co-localization analysis to design engagers that fire only where both signals are present.
Degraders (DACs)
Identifies dual-target zones co-localizing with E3 ligase — refining degrader delivery and selectivity.
USE CASES
Use PortraiTARGET to:
Five concrete outcomes our partners pursue with the platform.
Discover novel tumor-specific targets
Surface targets standard bulk-RNA pipelines miss, validated against intra-tumoral spatial context and whole-body toxicity signals.
Design ADC/RPT payload strategies
Use real tissue spatial data — not idealized assumptions — to pair payloads, linkers, and isotopes with the spatial biology of the actual tumor.
Build co-development-ready assets
Identify clinical indications and biomarkers for patient stratification, with pre-validated efficacy and safety metrics ready for partnership.
PARTNER WITH PORTRAI
Co-develop the next ADC, RPT, or degrader.
Portrai partners with biotech and pharma teams to apply PortraiTARGET to internal candidate lists and build smarter, safer therapies — with a physics-aware drug design approach.